Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Emisphere, Novo Nordisk sign oral insulin deal

Executive Summary

Drug delivery company Emisphere Technologies Inc. will use its Eligen drug delivery platform to develop oral versions of Danish biotech Novo Nordisk AS's insulin for diabetes.
Deal Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Intra-Biotech Deal

Related Companies

Advertisement
UsernamePublicRestriction

Register